The Effect of a Synthetic Estrogen, Ethinylestradiol, on the hERG Block by E-4031
暂无分享,去创建一个
K. Fukuda | J. Kurokawa | M. Ieda | Fumiya Tamura | K. Sakamoto | Mana Sugimoto | Masahiko Yamaguchi | Takeshi Suzuki | Shintaro Sugimoto
[1] D. Trégouët,et al. Association of Oral Contraceptives With Drug-Induced QT Interval Prolongation in Healthy Nonmenopausal Women , 2018, JAMA cardiology.
[2] Kevin R. DeMarco,et al. A multiscale computational modelling approach predicts mechanisms of female sex risk in the setting of arousal‐induced arrhythmias , 2017, The Journal of physiology.
[3] Beiyan Zou,et al. Investigation of miscellaneous hERG inhibition in large diverse compound collection using automated patch-clamp assay , 2016, Acta Pharmacologica Sinica.
[4] N. Harada,et al. Aromatase knockout mice reveal an impact of estrogen on drug-induced alternation of murine electrocardiography parameters. , 2015, The Journal of toxicological sciences.
[5] T. Furukawa,et al. Sex and gender aspects in antiarrhythmic therapy. , 2012, Handbook of experimental pharmacology.
[6] T. Furukawa,et al. A receptor-independent effect of estrone sulfate on the HERG channel. , 2009, Journal of pharmacological sciences.
[7] N. Harada,et al. Acute effects of oestrogen on the guinea pig and human IKr channels and drug‐induced prolongation of cardiac repolarization , 2008, The Journal of physiology.
[8] Ken Asada,et al. Progesterone Regulates Cardiac Repolarization Through a Nongenomic Pathway: An In Vitro Patch-Clamp and Computational Modeling Study , 2007, Circulation.
[9] T. Saikawa,et al. Influence of Menstrual Cycle on QT Interval Dynamics , 2006, Pacing and clinical electrophysiology : PACE.
[10] J. Nerbonne,et al. Molecular physiology of cardiac repolarization. , 2005, Physiological reviews.
[11] T. Furukawa,et al. Nontranscriptional Regulation of Cardiac Repolarization Currents by Testosterone , 2005, Circulation.
[12] M. W. van den Heuvel,et al. Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive. , 2005, Contraception.
[13] P. Greenland,et al. Estrogen and Progestin Use and the QT Interval in Postmenopausal Women , 2004, Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc.
[14] R. Kass,et al. K+ channel structure-activity relationships and mechanisms of drug-induced QT prolongation. , 2003, Annual review of pharmacology and toxicology.
[15] M. Hiraoka,et al. Effects of Na+ Channel Blocker, Pilsicainide, on HERG Current Expressed in HEK‐293 Cells , 2003, Journal of cardiovascular pharmacology.
[16] Mirei Nagai,et al. Dissociation of E-4031 from the HERG channel caused by mutations of an amino acid results in greater block at high stimulation frequency. , 2003, Cardiovascular research.
[17] J. Herman,et al. Pharmacology and toxicology of ethinyl estradiol and norethindrone acetate in experimental animals. , 2001, Regulatory toxicology and pharmacology : RTP.
[18] J. Pezzullo,et al. Drug-induced QT prolongation in women during the menstrual cycle. , 2001, JAMA.
[19] S. Priori,et al. Evidence for a Cardiac Ion Channel Mutation Underlying Drug‐Induced QT Prolongation and Life‐Threatening Arrhythmias , 2000, Journal of cardiovascular electrophysiology.
[20] M. Lazdunski,et al. Involvement of IsK-associated K+ channel in heart rate control of repolarization in a murine engineered model of Jervell and Lange-Nielsen syndrome. , 1998, Circulation research.
[21] M. Lehmann,et al. Sex difference in risk of torsade de pointes with d,l-sotalol. , 1996, Circulation.
[22] M. Sanguinetti,et al. A mechanistic link between an inherited and an acquird cardiac arrthytmia: HERG encodes the IKr potassium channel , 1995, Cell.
[23] M. Lehmann,et al. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. , 1993, JAMA.